- Home
- AACG vs CLDI Comparison
AACG vs CLDI Comparison
Compare AACG & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CLDI
- Stock Information
- Founded
- AACG 1999
- CLDI 2014
- Country
- AACG China
- CLDI United States
- Employees
- AACG N/A
- CLDI N/A
- Industry
- AACG Other Consumer Services
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AACG Real Estate
- CLDI Health Care
- Exchange
- AACG Nasdaq
- CLDI Nasdaq
- Market Cap
- AACG 24.4M
- CLDI 20.2M
- IPO Year
- AACG N/A
- CLDI N/A
- Fundamental
- Price
- AACG $1.96
- CLDI $5.30
- Analyst Decision
- AACG
- CLDI
- Analyst Count
- AACG 0
- CLDI 0
- Target Price
- AACG N/A
- CLDI N/A
- AVG Volume (30 Days)
- AACG 690.5K
- CLDI 961.3K
- Earning Date
- AACG 08-06-2025
- CLDI 08-08-2025
- Dividend Yield
- AACG N/A
- CLDI N/A
- EPS Growth
- AACG N/A
- CLDI N/A
- EPS
- AACG N/A
- CLDI N/A
- Revenue
- AACG $39,064,701.00
- CLDI N/A
- Revenue This Year
- AACG N/A
- CLDI N/A
- Revenue Next Year
- AACG N/A
- CLDI N/A
- P/E Ratio
- AACG N/A
- CLDI N/A
- Revenue Growth
- AACG 15.19
- CLDI N/A
- 52 Week Low
- AACG $0.50
- CLDI $2.43
- 52 Week High
- AACG $2.30
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- AACG 60.72
- CLDI 44.17
- Support Level
- AACG $1.42
- CLDI $4.85
- Resistance Level
- AACG $2.13
- CLDI $6.06
- Average True Range (ATR)
- AACG 0.38
- CLDI 1.03
- MACD
- AACG 0.04
- CLDI -0.31
- Stochastic Oscillator
- AACG 72.58
- CLDI 8.91
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.